ClinicalTrials.gg

Program

ribupatide

Also written as “HRS9531”, “HRS9531 injection” and “HRS9531 Tablet”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Kidney Failure, Chronic · Atherosclerosis · Fatty Liver, led by 2 companies.

Furthest: phase 3, since Apr 30, 202438 company-led studies, 19 open or runningLicense: Hengrui → Kailera, May 2024Next primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine3214 open or runningphase 3since Apr 30, 2024Nov 29, 2021Dec 2026phase 3 · NCT06994650
Kailera65 open or runningphase 3since Dec 9, 2025Jun 23, 2025May 2027phase 2 · NCT07458269
  • Named in Jiangsu HengRui Medicine’s own pipeline as Ribupatide, phase 4, as of Jul 31, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 22 studies since Nov 29, 2021.

  1. May 20, 2025Phase 3 study in Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP TherapyJiangsu HengRui Medicine · NCT06994650 · 144 enrolled · China
  2. Jun 22, 2025Phase 3 study in Diabetes Mellitus, Type 2Jiangsu HengRui Medicine · NCT07060456 · 300 planned · China
  3. Jun 23, 2025Kailera's first study: phase 1 study in OverweightNew to KaileraKailera · NCT07044401 · 51 enrolled · United States
  4. Aug 27, 2025Phase 1 study in OverweightJiangsu HengRui Medicine · NCT07150962 · 168 planned · China
  5. Dec 3, 2025Phase 3 study in ObesityJiangsu HengRui Medicine · NCT07285902 · 572 enrolled · China
  6. Dec 9, 20253 phase 3 studies in ObesityPhase 3 reachedKailera · NCT07284979, NCT07284901, NCT07284875
  7. Mar 3, 2026Phase 2 study in ObesityKailera · NCT07458269 · 264 enrolled · United States
  8. Apr 13, 2026Phase 1 study in Diabetes MellitusJiangsu HengRui Medicine · NCT07540754 · 24 planned · China
  9. Apr 17, 2026Phase 3 study in AtherosclerosisJiangsu HengRui Medicine · NCT07551492 · 9,262 planned · China
  10. May 11, 2026Phase 2 study in T2DMJiangsu HengRui Medicine · NCT07599410 · 240 planned · China
  11. Jun 16, 2026Phase 2 study in Metabolic Dysfunction-Associated Steatohepatitis (MASH)Jiangsu HengRui Medicine · NCT07660848 · 160 planned · China
  12. Jun 22, 2026Phase 3 study in Chronic Management of Body WeightJiangsu HengRui Medicine · NCT07670884 · 675 planned · China
  13. Jul 8, 2026Phase 3 study in Osteoarthritis, KneeJiangsu HengRui Medicine · NCT07709910 · 382 planned · China
  14. Aug 25, 2026Phase 1 study in Kidney Failure, ChronicKailera · NCT07793929 · 32 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 3 study in Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP TherapyJiangsu HengRui Medicine · NCT06994650
  2. Dec 2026Primary completion: phase 3 study in Sleep Apnea, ObstructiveJiangsu HengRui Medicine · NCT06974851
  3. Jan 2027Primary completion: phase 1 study in Diabetes MellitusJiangsu HengRui Medicine · NCT07540754
  4. Feb 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2Jiangsu HengRui Medicine · NCT07060456

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 38 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07793929Kidney Failure, Chronic · United States1RecruitingKaileraFeb 8, 202832
NCT07709910Osteoarthritis, Knee · China3Not yet recruitingJiangsu HengRui MedicineNov 2028382
NCT07670884Chronic Management of Body Weight · China3RecruitingJiangsu HengRui MedicineOct 31, 2027675
NCT07660848Metabolic Dysfunction-Associated Steatohepatitis (MASH) · China2RecruitingJiangsu HengRui MedicineMar 2028160
NCT07599410T2DM · China2RecruitingJiangsu HengRui MedicineMay 2027240
NCT07551492Atherosclerosis · China3RecruitingJiangsu HengRui MedicineMay 24, 20319,262
NCT07540754Diabetes Mellitus · China1RecruitingJiangsu HengRui MedicineJan 202724
NCT07458269Obesity · United States2Active, not recruitingKaileraMay 2027264
NCT07284979Obesity · United States, Australia, Bulgaria and more3Active, not recruitingKaileraMar 20281,270
NCT07284901Obesity · United States, Argentina, Australia and more3Active, not recruitingKaileraMar 27, 20281,270
NCT07284875Obesity · United States, Argentina, Australia and more3Active, not recruitingKaileraFeb 20282,530
NCT07285902Obesity · China3Active, not recruitingJiangsu HengRui MedicineMar 2027572
NCT07150962Overweight · China1RecruitingJiangsu HengRui MedicineFeb 2026168
NCT07044401Overweight · United States1CompletedKaileraNov 13, 202551
NCT07060456Diabetes Mellitus, Type 2 · China3RecruitingJiangsu HengRui MedicineFeb 2027300
NCT06994650Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy · China3Active, not recruitingJiangsu HengRui MedicineDec 2026144
NCT06974851Sleep Apnea, Obstructive · China3RecruitingJiangsu HengRui MedicineDec 2026140
NCT06855147Diabetes Mellitus, Type 2 · China1CompletedJiangsu HengRui MedicineJun 17, 20257
NCT06841445Chronic Management of Body Weight · China2CompletedJiangsu HengRui MedicineJan 8, 2026166
NCT06792955Overweight · China1CompletedJiangsu HengRui MedicineJun 6, 2025120
NCT06762600Overweight · China1CompletedJiangsu HengRui MedicineMar 12, 2026102
NCT06723691Diabetes Mellitus, Type 2 · China1CompletedJiangsu HengRui MedicineJun 9, 202557
NCT06654960Diabetes Mellitus, Type 2 · China1CompletedJiangsu HengRui MedicineDec 26, 202420
NCT06650007Diabetes Mellitus, Type 2 · China3CompletedJiangsu HengRui MedicineJan 21, 2026218
NCT06649344Diabetes Mellitus, Type 2 · China3CompletedJiangsu HengRui MedicineJul 18, 2026884
NCT06595797Obese Subjects With Polycystic Ovary Syndrome (PCOS)2UNKNOWNJiangsu HengRui MedicineDec 2025144
NCT06565871Weight Management2Not yet recruitingJiangsu HengRui MedicineDec 2025108
NCT06506175Diabetes Mellitus, Type 2 · China1Not yet recruitingJiangsu HengRui MedicineSep 2026100
NCT06435676Overweight · China1CompletedJiangsu HengRui MedicineOct 8, 202472
NCT06396429Overweight · China3CompletedJiangsu HengRui MedicineJul 7, 2025567
NCT06391710Heart Failure With Preserved Ejection Fraction · China2Active, not recruitingJiangsu HengRui MedicineJan 2026203
NCT06246175Diabetes Mellitus, Type 2 · China1CompletedJiangsu HengRui MedicineSep 2, 202532
NCT06054698Overweight · China2CompletedJiangsu HengRui MedicineSep 9, 202461
NCT05966272Diabetes Mellitus, Type 2 · China2CompletedJiangsu HengRui MedicineSep 24, 2024199
NCT05881837Overweight · China2CompletedJiangsu HengRui MedicineOct 13, 2024249
NCT05893576Diabetes Mellitus, Type 2 · China1CompletedJiangsu HengRui MedicineSep 4, 202350
NCT05516966Diabetes Mellitus, Type 2 · China1CompletedJiangsu HengRui MedicineMay 24, 202364
NCT05152277Diabetes Mellitus, Type 2 · China1CompletedJiangsu HengRui MedicineAug 24, 202290

How it is read

Names in the registry

  • “HRS9531”, 16 entries
  • “HRS9531 injection”, 14 entries
  • “HRS9531 Tablet”, 9 entries
  • “HRS9531 Injection”, 6 entries
  • “Ribupatide”, 5 entries

Codes read as this program: HRS9531.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.